Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Journal of Pharmaceutical Care Anwar Medika

KOMPLIKASI EMBOLI PARU PADA CORONA VIRUS DISEASE 2019 (COVID – 19) : Sebuah Tinjauan Literatur Nurdianto, Arif Rahman
Journal of Pharmaceutical Care Anwar Medika (J-PhAM) Vol 4 No 1 (2021): Journal of Pharmaceutical Care Anwar Medika
Publisher : STIKES Rumah Sakit Anwar Medika

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36932/jpcam.v4i1.72

Abstract

Background: The respiratory disease that attacks respiratory system makes a high mortality rate which one of the complications of its manifestation is thrombotic in the amount of 31% , where from all these complications, 87% of which are pulmonal embolic. It is an emergency state that can cause death and as it needs fast, accurate diagnostic and handling for better outcome for the patients.MethodThis Study compares many sources form research articles, case reports, and international journal reviews.Result: Scoring, D dimer, and the other imaging examination that available at health center can be used together for Covid 19 screening to find out pulmonal embolism as a Covid 19 complication.Conclusion: the accurate dan precise pulmonal embolism in Covid 19 used scoring and imaging that available in the health center makes the prompt treatment dan makes a better outcome.
Penanganan Pasien COVID-19 dengan Schizofrenia di Wilayah Kerja Puskesmas Trosobo (Laporan Kasus) Nurdianto, Arif Rahman
Journal of Pharmaceutical Care Anwar Medika (J-PhAM) Vol 4 No 1 (2021): Journal of Pharmaceutical Care Anwar Medika
Publisher : STIKES Rumah Sakit Anwar Medika

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36932/jpcam.v4i1.80

Abstract

Background: Schizophrenia patients infected with COVID-19 have become a problem in handling COVID-19 at the Sidoarjo regency community health center. Selection of drugs and handling of patients with their environment requires a different approach from normal patients. Research on COVID-19 with schizophrenia patients is very limited. The COVID-19 pandemic makes patient services and access unlike before the pandemic and is very limited so that access to schizophrenia patients, both controlled and uncontrolled, is still lacking and the effectiveness of therapy in schizophrenia patients with COVID-19 also still needs much research. Objective: Conduct a comprehensive study on how to diagnose, pathogenesis, therapy, and rehabilitate schizophrenia patients with COVID-19 infection Case report: Schizophrenia patients who were confirmed with COVID-19 through rRT-PCR examination were isolated at home and treated with medical treatment to overcome existing complaints, then given an injection of short-acting anti-anxiety drugs followed by maintenance therapy. Patients are treated at home by the puskesmas by involving their families and communities until they recover. Discussion: Schizophrenia patients are at risk of being infected with COVID-19 due to cognitive and behavioral disorders. Schizophrenia patients infected with COVID-19 must be given medical therapy based on complaints or negative symptoms that arise such as psychotic disorders or complaints caused by COVID-19 infection. Chlorpromazine (CPZ) can reduce psychotic disorders and hallucinations in these patients. Haloperidol can reduce positive symptoms that arise in patients so that patients can be calmer. Clobazam acts as a Gamma Amino Butyric Acid (GABA) which can reduce anxiety and agitation. Citicoline helps increase blood flow and oxygen consumption in the brain so that negative symptoms can be suppressed. Psychotherapy, family, and environmental support are needed to reduce psychosocial problems that arise due to COVID-19. Conclusions: Therapy of schizophrenia patients with COVID-19 is adjusted to psychotic problems and complaints due to COVID-19. A family-based therapy approach is needed during the isolation period to post COVID-19 health care.
COMPARISON OF ANTIMICROBIAL EFFICACY OF HONEY GEL AND CLOTRIMAZOLE CREAM IN THE TREATMENT OF VULVOVAGINAL CANDIDIASIS SYMPTOMS Arif Rahman Nurdianto; Heryanti Pusparisa; Hotimah Masdan Salim; Joko Sulistyo
Journal of Pharmaceutical Care Anwar Medika (J-PhAM) Vol 4 No 2 (2022): Journal of Pharmaceutical Care Anwar Medika
Publisher : STIKES Rumah Sakit Anwar Medika

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36932/jpcam.v4i2.94

Abstract

The available literature regarding the epidemiological or clinical features of vulvovaginal candidiasis (VVC) in most women will experience episodes of vulvovaginal candidiasis in their lifetime, 50% of whom will experience at least a second episode, and 5-10% of all women will experience recurrent vulvovaginal candidiasis (≥ 4 episode / 1 year). Vulvovaginal candidiasis is known as one of the most common yeast infections in women of reproductive age and is considered an important public health problem. In recent years, due to resistance to common antifungal drugs, the use of traditional antifungal medicines and herbal remedies has increased. Therefore this system aimed to investigate the effect of honey vaginal gel/ointment and to compare it with clotrimazole vaginal cream on symptoms of vulvovaginal candidiasis in patients. Vaginal clotrimazole is the drug of choice for the treatment of VVC. However, the increasing drug resistance to these microorganisms has led to greater interest in naturally occurring antifungal drugs. This systematic literature was conducted to compare vaginal honey ointment/gel and clotrimazole vaginal cream for the treatment of VVC.